查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1930043

马匹健康市场规模、占有率、成长及全球产业分析：按类型、应用和地区划分的洞察与预测（2025-2034）

Equine Health Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 164 Pages | 商品交期: 请询问到货日

价格

马匹健康市场成长驱动因素

全球马匹健康市场专注于透过使用药物、疫苗和饲料添加剂来预防、诊断和治疗影响马匹的疾病。马匹容易受到多种传染性和非传染性疾病的侵袭，其中一些是地方性流行病，有些则是由环境变化和人畜共患病风险引起的。疾病流行率上升、人们对马匹福利的意识不断增强以及政府和机构支持力度加大，正推动全球马匹健康市场稳步增长。

市场规模及预测

根据 Fortune Business Insights 数据显示，2025 年全球马匹健康市场规模为 22.1 亿美元。预计到 2026 年将成长至 23.6 亿美元，并在 2034 年进一步扩大至 40.8 亿美元，在预测期（2026-2034 年）内复合年增长率 (CAGR) 为 7.07%。

北美地区在全球市场中占领先地位，预计到 2025 年将占 37.43% 的市场占有率，这主要得益于其庞大的马匹数量、先进的兽医基础设施以及马匹保健产品的高普及率。

市场驱动因素

市场成长的主要驱动因素是马匹疾病的增加，包括西尼罗河病毒、马流感、狂犬病、疱疹病毒、破伤风和波托马克马热。根据美国农业部统计，2019年美国确诊了90例西尼罗河病毒感染病例和184例东部马脑炎病例。这些疾病爆发的增加显着提高了对预防性疫苗和治疗的需求。

此外，人们对人畜共患病传播的认识不断提高，兽医组织和政府的措施也促进了常规疫苗接种和预防保健。加大研发投入以提高疫苗安全性和药物有效性也有助于市场扩张。

新冠疫情的影响

新冠疫情对马匹健康市场的影响程度为中等。 2020年，由于供应链中断、旅行限制以及兽医到访马场次数减少，市场成长放缓。然而，随着疫情后期兽医院和诊所的重新开放，市场出现了小幅正成长。

例如，硕腾服务有限公司（Zoetis Services LLC）2020年在马匹领域的净销售额为2.15亿美元，2021年较上年增长22.3%。随着兽医诊所恢復正常运营，预计市场将在2021年和2022年恢復到疫情前的成长轨道，从而稳定收入并支持长期成长。

市场趋势

马匹健康市场最显着的趋势之一是向鼻内给药的转变。鼻内疫苗可以减轻肌肉酸痛并增强局部免疫力，尤其是在预防呼吸道疾病方面。

例如，2020 年 9 月，勃林格殷格翰推出了 Aservo EquiHaler，这是首个获得美国食品药物管理局 (FDA) 批准用于治疗严重马哮喘的吸入式疫苗。领先企业持续的技术创新和开创性产品的推出正在推动市场成长。

成长驱动因素

马匹疾病发生率的快速成长仍然是关键的成长驱动因素。英国的马流感等地方性疾病以及全球病毒性疾病的爆发日益增多，正在推动对疫苗和药物的需求。此外，诸如英国马术联合会发起的 "降低疾病风险联合倡议" （2022 年）等提高公众意识的活动，正在推广预防性医疗保健措施，进一步支持市场成长。

限制因子

儘管成长前景强劲，但合格的马兽医短缺仍然是一个挑战，尤其是在新兴地区和农村地区。根据澳洲广播公司新闻（ABC News，2023）报道，澳洲只有2-3%的兽医毕业生会专攻马科医学，限制了马匹获得医疗服务的机会。

此外，由于操作不当、免疫反应差异和病原体变异等因素导致的疫苗失效案例，引起了马主的担忧，并可能限制产品的使用。

细分市场分析

  • 依药物类别划分：2026年，製药类药物占市场主导地位，市占率达54.78%。这主要得益于强大的研发实力和新产品上市，例如维克（Virbac）的类固醇片剂 "Equipred" 。
  • 依疾病分类：其他疾病类别占市场主导地位，涵盖诸如腹痛、跛行和莱姆病等疾病。马流感类别在2026年占了21.36%的市场。
  • 依分销管道分类：兽医医院和诊所占最大占有率，这主要得益于全球专业马科诊所数量的成长。

区域洞察

2026年，北美市场规模将达到8.8亿美元，主要得益于美国约720万匹马的庞大数量。欧洲由于马流感等疾病的爆发，继续占有重要占有率。亚太地区预计将以最高的复合年增长率增长，这主要得益于中国、日本和印度的强劲增长，以及公众意识的提高和政府举措的支持。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 统计：主要国家/地区马匹数量（2025 年）
  • 主要国家/地区马匹健康监管环境（2025 年）
  • 主要产业趋势（併购、合作、新产品发表等）
  • 马匹健康管理技术进步
  • 新冠疫情的影响市场

第五章 全球马匹健康市场分析、洞察与预测（2021-2034）

  • 市场分析、洞察与预测 - 按产品分类
    • 依药物类型分类
      • 抗感染药
      • 抗发炎药
      • 驱虫药
      • 其他
    • 疫苗类型分类
      • 灭活​​疫苗
      • 减毒活疫苗
      • 重组疫苗
      • 其他
    • 饲料添加剂
  • 市场分析、洞察与预测 - 按疾病类型分类
    • 西尼罗河病毒
    • 马狂犬病
    • 马流感
    • 马疱疹病毒
    • 波托马克河马热
    • 破伤风
    • 其他
  • 市场分析、洞察与预测 - 按销售管道划分
    • 兽医院和诊所
    • 零售药局和药房
    • 其他
  • 市场分析、洞察与预测 - 按地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美马匹健康市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲马匹健康市场分析、洞察与预测预测，2021-2034

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章：亚太地区马匹健康市场分析、洞察与预测，2021-2034

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲马匹健康市场分析、洞察与预测，2021-2034

  • 依国家/地区
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家/地区

第十章：中东和非洲马匹健康市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会 (GCC)
    • 南非
    • 其他中东和非洲国家/地区

第十一章：竞争分析

  • 全球市占率分析（2025）
  • 公司简介
    • 硕腾服务有限公司 (Zoetis Services LLC)
    • 雪华 (Ceva)
    • 礼来 (Elanco)
    • 勃林格殷格翰国际有限公司 (Boehringer Ingelheim International GmbH)
    • 维托奎诺 (Vetoquinol)
    • 新健公司 (Neogen Corporation)
    • 维克 (Virbac)
    • 默克公司 (Merck & Co.)公司
    • 诺布鲁克
    • 普瑞纳动物营养股份有限公司
    • 京日製药株式会社
    • 英国马匹产品股份有限公司
Product Code: FBI101416

Growth Factors of equine health Market

The global equine health market focuses on the prevention, diagnosis, and treatment of diseases affecting horses through the use of drugs, vaccines, and supplemental feed additives. Horses are vulnerable to a wide range of infectious and non-infectious diseases, some of which are endemic, while others emerge due to environmental changes and zoonotic risks. Rising disease prevalence, growing awareness of equine welfare, and increasing government and institutional support are driving steady growth in the global equine health market.

Market Size and Forecast

According to Fortune Business Insights, the global equine health market was valued at USD 2.21 billion in 2025. The market is projected to grow to USD 2.36 billion in 2026 and further expand to USD 4.08 billion by 2034, registering a CAGR of 7.07% during the forecast period (2026-2034).

North America dominated the global market with a share of 37.43% in 2025, supported by a strong equine population, advanced veterinary infrastructure, and high adoption of equine healthcare products.

Market Drivers

A major driver of market growth is the increasing prevalence of equine diseases, including West Nile virus, equine influenza, rabies, herpes virus, tetanus, and Potomac horse fever. According to the U.S. Department of Agriculture, there were 90 cases of West Nile virus and 184 cases of eastern equine encephalitis in the U.S. in 2019. Such disease incidence has significantly increased the demand for preventive vaccines and therapeutic drugs.

Additionally, growing awareness of zoonotic disease transmission and initiatives by veterinary organizations and governments are encouraging regular vaccination and preventive care. Rising investments in research and development (R&D) to improve vaccine safety and drug efficacy are also contributing to market expansion.

COVID-19 Impact

The COVID-19 pandemic had a moderate impact on the equine health market. In 2020, growth slowed due to supply chain disruptions, travel restrictions, and reduced veterinary visits to equine farms. However, the market witnessed slight positive growth as veterinary hospitals and clinics resumed operations in the second half of the pandemic.

For instance, Zoetis Services LLC generated USD 215.0 million in net sales from its horse segment in 2020, followed by a 22.3% year-on-year increase in 2021. As veterinary visits normalized, the market returned to its pre-COVID growth trajectory by 2021-2022, stabilizing revenues and supporting long-term growth.

Market Trends

One of the most prominent trends in the equine health market is the shift toward intranasal routes of administration. Intranasal vaccines reduce muscle soreness and enhance local immunity, particularly for respiratory diseases.

For example, in September 2020, Boehringer Ingelheim launched Aservo EquiHaler, the first FDA-approved inhalant therapy for horses with severe equine asthma. Continuous innovation and advanced product launches by key players are accelerating market growth.

Growth Factors

The surge in equine disease prevalence remains a key growth factor. Endemic diseases such as equine influenza in the U.K. and increasing viral outbreaks globally are driving demand for vaccines and drugs. Moreover, rising awareness initiatives, such as the British Equestrian's "Reducing Disease Risk Together" campaign (2022), are improving adoption of preventive healthcare practices, further boosting market growth.

Restraining Factors

Despite strong growth prospects, the market faces challenges due to the shortage of qualified equine veterinarians, especially in emerging and rural regions. According to ABC News (2023), only 2-3% of new veterinary graduates in Australia pursue equine medicine, limiting access to equine care services.

Additionally, vaccine failure events, caused by factors such as improper handling, immune response variability, or pathogen mutation, have raised concerns among horse owners, potentially restricting product adoption.

Segmentation Analysis

  • By Product: The drug class segment dominated the market with a 54.78% share in 2026, driven by strong R&D and product launches such as Virbac's Equipred steroid tablets.
  • By Disease Type: The others segment led the market, covering diseases such as colic, lameness, and Lyme disease. The equine influenza segment accounted for 21.36% share in 2026.
  • By Distribution Channel: Veterinary hospitals and clinics held the largest share due to the growing number of specialized equine clinics globally.

Regional Insights

In 2026, North America generated USD 0.88 billion, driven by a large equine population of approximately 7.2 million horses in the U.S. Europe maintained a significant share due to disease outbreaks such as equine influenza. Asia Pacific is expected to grow at the fastest CAGR, with strong growth in China, Japan, and India, supported by increasing awareness and government initiatives.

Competitive Landscape

The market is fragmented, with key players including Zoetis Services LLC, Boehringer Ingelheim, Merck & Co., Dechra, Elanco, and Virbac. Companies are focusing on new product launches, geographic expansion, and strategic partnerships to strengthen their market presence.

Conclusion

In conclusion, the global equine health market is projected to grow from USD 2.21 billion in 2025 to USD 4.08 billion by 2034, driven by rising disease prevalence, increasing awareness of equine welfare, and continuous innovation in drugs and vaccines. While challenges such as veterinarian shortages and vaccine efficacy concerns persist, expanding preventive healthcare initiatives, advanced treatment options, and strategic efforts by key players are expected to support sustained market growth throughout the forecast period.

Segmentation By Product

  • Drug Class
    • Anti-Infective
    • Anti-Inflammatory
    • Parasiticides
    • Others
  • Vaccines
    • Inactivated
    • Live Attenuated
    • Recombinant
    • Others
  • Supplemental Feed Additives

By Disease Type

  • West Nile Virus
  • Equine Rabies
  • Equine Influenza
  • Equine Herpes Virus
  • Potomac Horse Fever
  • Tetanus
  • Others

By Distribution Channel

  • Veterinary Hospitals and Clinics
  • Retail Pharmacies and Drug Stores
  • Others

By Region

  • North America (By Product, Disease Type, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Product, Disease Type, Distribution Channel, and Country/Sub-Region)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Disease Type, Distribution Channel, and Country/Sub-Region)
    • China
    • India
    • Japan
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Disease Type, Distribution Channel, and Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa (By Product, Disease Type, Distribution Channel, and Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Statistics: Equine Population, By Key Countries, 2025
  • 4.2. Regulatory Scenario, Equine Health, By Key Countries, 2025
  • 4.3. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)
  • 4.4. Technology Advances in Equine Health
  • 4.5. Impact of Covid-19 on the Market

5. Global Equine Health Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Drug Type
      • 5.1.1.1. Anti-Infectives
      • 5.1.1.2. Anti-Inflammatory
      • 5.1.1.3. Parasiticides
      • 5.1.1.4. Others
    • 5.1.2. Vaccine Type
      • 5.1.2.1. Inactivated
      • 5.1.2.2. Live Attenuated
      • 5.1.2.3. Recombinant
      • 5.1.2.4. Others
    • 5.1.3. Supplemental Feed Additives
  • 5.2. Market Analysis, Insights and Forecast - By Disease Type
    • 5.2.1. West Nile Virus
    • 5.2.2. Equine Rabies
    • 5.2.3. Equine Influenza
    • 5.2.4. Equine Herpes Virus
    • 5.2.5. Potomac Horse Fever
    • 5.2.6. Tetanus
    • 5.2.7. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Veterinary Hospitals and Clinics
    • 5.3.2. Retail Pharmacies and Drug Stores
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Equine Health Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Drug Type
      • 6.1.1.1. Anti-Infectives
      • 6.1.1.2. Anti-Inflammatory
      • 6.1.1.3. Parasiticides
      • 6.1.1.4. Others
    • 6.1.2. Vaccine Type
      • 6.1.2.1. Inactivated
      • 6.1.2.2. Live Attenuated
      • 6.1.2.3. Recombinant
      • 6.1.2.4. Others
    • 6.1.3. Supplemental Feed Additives
  • 6.2. Market Analysis, Insights and Forecast - By Disease Type
    • 6.2.1. West Nile Virus
    • 6.2.2. Equine Rabies
    • 6.2.3. Equine Influenza
    • 6.2.4. Equine Herpes Virus
    • 6.2.5. Potomac Horse Fever
    • 6.2.6. Tetanus
    • 6.2.7. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Veterinary Hospitals and Clinics
    • 6.3.2. Retail Pharmacies and Drug Stores
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Equine Health Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Drug Type
      • 7.1.1.1. Anti-Infectives
      • 7.1.1.2. Anti-Inflammatory
      • 7.1.1.3. Parasiticides
      • 7.1.1.4. Others
    • 7.1.2. Vaccine Type
      • 7.1.2.1. Inactivated
      • 7.1.2.2. Live Attenuated
      • 7.1.2.3. Recombinant
      • 7.1.2.4. Others
    • 7.1.3. Supplemental Feed Additives
  • 7.2. Market Analysis, Insights and Forecast - By Disease Type
    • 7.2.1. West Nile Virus
    • 7.2.2. Equine Rabies
    • 7.2.3. Equine Influenza
    • 7.2.4. Equine Herpes Virus
    • 7.2.5. Potomac Horse Fever
    • 7.2.6. Tetanus
    • 7.2.7. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Veterinary Hospitals and Clinics
    • 7.3.2. Retail Pharmacies and Drug Stores
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Equine Health Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Drug Type
      • 8.1.1.1. Anti-Infectives
      • 8.1.1.2. Anti-Inflammatory
      • 8.1.1.3. Parasiticides
      • 8.1.1.4. Others
    • 8.1.2. Vaccine Type
      • 8.1.2.1. Inactivated
      • 8.1.2.2. Live Attenuated
      • 8.1.2.3. Recombinant
      • 8.1.2.4. Others
    • 8.1.3. Supplemental Feed Additives
  • 8.2. Market Analysis, Insights and Forecast - By Disease Type
    • 8.2.1. West Nile Virus
    • 8.2.2. Equine Rabies
    • 8.2.3. Equine Influenza
    • 8.2.4. Equine Herpes Virus
    • 8.2.5. Potomac Horse Fever
    • 8.2.6. Tetanus
    • 8.2.7. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Veterinary Hospitals and Clinics
    • 8.3.2. Retail Pharmacies and Drug Stores
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. Japan
    • 8.4.2. China
    • 8.4.3. India
    • 8.4.4. Australia
    • 8.4.5. Southeast Asia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Equine Health Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Drug Type
      • 9.1.1.1. Anti-Infectives
      • 9.1.1.2. Anti-Inflammatory
      • 9.1.1.3. Parasiticides
      • 9.1.1.4. Others
    • 9.1.2. Vaccine Type
      • 9.1.2.1. Inactivated
      • 9.1.2.2. Live Attenuated
      • 9.1.2.3. Recombinant
      • 9.1.2.4. Others
    • 9.1.3. Supplemental Feed Additives
  • 9.2. Market Analysis, Insights and Forecast - By Disease Type
    • 9.2.1. West Nile Virus
    • 9.2.2. Equine Rabies
    • 9.2.3. Equine Influenza
    • 9.2.4. Equine Herpes Virus
    • 9.2.5. Potomac Horse Fever
    • 9.2.6. Tetanus
    • 9.2.7. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Veterinary Hospitals and Clinics
    • 9.3.2. Retail Pharmacies and Drug Stores
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Equine Health Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Drug Type
      • 10.1.1.1. Anti-Infectives
      • 10.1.1.2. Anti-Inflammatory
      • 10.1.1.3. Parasiticides
      • 10.1.1.4. Others
    • 10.1.2. Vaccine Type
      • 10.1.2.1. Inactivated
      • 10.1.2.2. Live Attenuated
      • 10.1.2.3. Recombinant
      • 10.1.2.4. Others
    • 10.1.3. Supplemental Feed Additives
  • 10.2. Market Analysis, Insights and Forecast - By Disease Type
    • 10.2.1. West Nile Virus
    • 10.2.2. Equine Rabies
    • 10.2.3. Equine Influenza
    • 10.2.4. Equine Herpes Virus
    • 10.2.5. Potomac Horse Fever
    • 10.2.6. Tetanus
    • 10.2.7. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Veterinary Hospitals and Clinics
    • 10.3.2. Retail Pharmacies and Drug Stores
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Zoetis Services LLC
      • 11.2.1.1. Overview
      • 11.2.1.2. Product
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. Ceva
      • 11.2.2.1. Overview
      • 11.2.2.2. Product
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Elanco
      • 11.2.3.1. Overview
      • 11.2.3.2. Product
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Boehringer Ingelheim International GmbH
      • 11.2.4.1. Overview
      • 11.2.4.2. Product
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Vetoquinol
      • 11.2.5.1. Overview
      • 11.2.5.2. Product
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. Neogen Corporation
      • 11.2.6.1. Overview
      • 11.2.6.2. Product
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. Virbac
      • 11.2.7.1. Overview
      • 11.2.7.2. Product
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Merck & Co., Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Product
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. financials (Based on Availability)
    • 11.2.9. Norbrook
      • 11.2.9.1. Overview
      • 11.2.9.2. Product
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. financials (Based on Availability)
    • 11.2.10. Purina Animal Nutrition LLC.
      • 11.2.10.1. Overview
      • 11.2.10.2. Product
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. financials (Based on Availability)
    • 11.2.11. Kyoritsuseiyaku Corporation
      • 11.2.11.1. Overview
      • 11.2.11.2. Product
      • 11.2.11.3. SWOT Analysis
      • 11.2.11.4. Recent Developments
      • 11.2.11.5. Strategies
      • 11.2.11.6. financials (Based on Availability)
    • 11.2.12. Equine Products UK Ltd.
      • 11.2.12.1. Overview
      • 11.2.12.2. Product
      • 11.2.12.3. SWOT Analysis
      • 11.2.12.4. Recent Developments
      • 11.2.12.5. Strategies
      • 11.2.12.6. financials (Based on Availability)

List of Tables

  • Table 01: Global Equine Health Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 02: Global Equine Health Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 03: Global Equine Health Market Revenue (USD billion) Forecast, By Vaccine Type, 2021-2034
  • Table 04: Global Equine Health Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 05: Global Equine Health Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 06: Global Equine Health Market Revenue (USD billion) Forecast, By Region, 2021-2034
  • Table 07: North America Equine Health Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 08: North America Equine Health Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 09: North America Equine Health Market Revenue (USD billion) Forecast, By Vaccine Type, 2021-2034
  • Table 10: North America Equine Health Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 11: North America Equine Health Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 12: North America Equine Health Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 13: Europe Equine Health Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 14: Europe Equine Health Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 15: Europe Equine Health Market Revenue (USD billion) Forecast, By Vaccine Type, 2021-2034
  • Table 16: Europe Equine Health Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 17: Europe Equine Health Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 18: Europe Equine Health Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 19: Asia Pacific Equine Health Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 20: Asia Pacific Equine Health Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 21: Asia Pacific Equine Health Market Revenue (USD billion) Forecast, By Vaccine Type, 2021-2034
  • Table 22: Asia Pacific Equine Health Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 23: Asia Pacific Equine Health Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 24: Asia Pacific Equine Health Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 25: Latin America Equine Health Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 26: Latin America Equine Health Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 27: Latin America Equine Health Market Revenue (USD billion) Forecast, By Vaccine Type, 2021-2034
  • Table 28: Latin America Equine Health Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 29: Latin America Equine Health Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 30: Latin America Equine Health Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034
  • Table 31: Middle East & Africa Equine Health Market Revenue (USD billion) Forecast, By Product, 2021-2034
  • Table 32: Middle East & Africa Equine Health Market Revenue (USD billion) Forecast, By Drug Type, 2021-2034
  • Table 33: Middle East & Africa Equine Health Market Revenue (USD billion) Forecast, By Vaccine Type, 2021-2034
  • Table 34: Sweden Equine Health Market Revenue (USD billion) Forecast, By Disease Type, 2021-2034
  • Table 35: Middle East & Africa Equine Health Market Revenue (USD billion) Forecast, By Distribution Channel, 2021-2034
  • Table 36: Middle East & Africa Equine Health Market Revenue (USD billion) Forecast, By Country/ Sub-Region, 2021-2034

List of Figures

  • Figure 01: Global Equine Health Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 02: Global Equine Health Market Value Share (%), By Product, 2025 & 2034
  • Figure 03: Global Equine Health Market Value Share (%), By Disease Type, 2025 & 2034
  • Figure 04: Global Equine Health Market Value Share (%), By Distribution Channel, 2025 & 2034
  • Figure 05: Global Equine Health Market Value Share (%), By Region, 2025 & 2034
  • Figure 06: North America Equine Health Market Value (USD billion), By Product, 2025 & 2034
  • Figure 07: North America Equine Health Market Value Share (%), By Product, 2025
  • Figure 08: North America Equine Health Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 09: North America Equine Health Market Value Share (%), By Disease Type, 2025
  • Figure 10: North America Equine Health Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 11: North America Equine Health Market Value Share (%), By Distribution Channel, 2025
  • Figure 12: North America Equine Health Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Equine Health Market Value Share (%), By Country, 2025
  • Figure 14: Europe Equine Health Market Value (USD billion), By Product, 2025 & 2034
  • Figure 15: Europe Equine Health Market Value Share (%), By Product, 2025
  • Figure 16: Europe Equine Health Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 17: Europe Equine Health Market Value Share (%), By Disease Type, 2025
  • Figure 18: Europe Equine Health Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 19: Europe Equine Health Market Value Share (%), By Distribution Channel, 2025
  • Figure 20: Europe Equine Health Market Value (USD billion), By Country/ Sub-Region, 2025 & 2034
  • Figure 21: Europe Equine Health Market Value Share (%), By Country/ Sub-Region, 2025
  • Figure 22: Asia Pacific Equine Health Market Value (USD billion), By Product, 2025 & 2034
  • Figure 23: Asia Pacific Equine Health Market Value Share (%), By Product, 2025
  • Figure 24: Asia Pacific Equine Health Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 25: Asia Pacific Equine Health Market Value Share (%), By Disease Type, 2025
  • Figure 26: Asia Pacific Equine Health Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Equine Health Market Value Share (%), By Distribution Channel, 2025
  • Figure 28: Asia Pacific Equine Health Market Value (USD billion), By Country/ Sub-Region, 2025 & 2034
  • Figure 29: Asia Pacific Equine Health Market Value Share (%), By Country/ Sub-Region, 2025
  • Figure 30: Latin America Equine Health Market Value (USD billion), By Product, 2025 & 2034
  • Figure 31: Latin America Equine Health Market Value Share (%), By Product, 2025
  • Figure 32: Latin America Equine Health Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 33: Latin America Equine Health Market Value Share (%), By Disease Type, 2025
  • Figure 34: Latin America Equine Health Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Equine Health Market Value Share (%), By Distribution Channel, 2025
  • Figure 36: Latin America Equine Health Market Value (USD billion), By Country/ Sub-Region, 2025 & 2034
  • Figure 37: Latin America Equine Health Market Value Share (%), By Country/ Sub-Region, 2025
  • Figure 38: Middle East & Africa Equine Health Market Value (USD billion), By Product, 2025 & 2034
  • Figure 39: Middle East & Africa Equine Health Market Value Share (%), By Product, 2025
  • Figure 40: Middle East & Africa Equine Health Market Value (USD billion), By Disease Type, 2025 & 2034
  • Figure 41: Middle East & Africa Equine Health Market Value Share (%), By Disease Type, 2025
  • Figure 42: Middle East & Africa Equine Health Market Value (USD billion), By Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Equine Health Market Value Share (%), By Distribution Channel, 2025
  • Figure 44: Middle East & Africa Equine Health Market Value (USD billion), By Country/ Sub-Region, 2025 & 2034
  • Figure 45: Middle East & Africa Equine Health Market Value Share (%), By Country/ Sub-Region, 2025
  • Figure 46: The figure besides highlights the market share (%) of companies operating in the global equine health market, 2025.